Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Results available

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NCT01851369
Conditions
Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions
TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Coronary Artery Disease
Interventions
regadenoson and atropine
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 2 Interventional Results available

Treating Respiratory Emergencies in Children Study

NCT06074185
Conditions
Asthma in Children
Interventions
Ipratropium Bromide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Charlotte, North Carolina • Salt Lake City, Utah
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
San Diego, California • Denver, Colorado • Wheat Ridge, Colorado + 12 more
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bronchospasm, Exercise-Induced
Interventions
ipratropium bromide, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Berkeley, California
Conditions
Epiphora
Interventions
Atropine ophthalmic solution
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Terminated Phase 3 Interventional Results available

Combined Patching-Atropine for Residual Amblyopia

NCT00506675
Conditions
Amblyopia
Interventions
Patching, Atropine
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 9 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhaled Atropine Sulfate in Healthy Adults

NCT00947596
Conditions
Organophosphorus Poisoning
Interventions
atropine sulfate
Drug
Lead sponsor
MicroDose Defense Products L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%, Macroduct sweat stimulator
Drug · Device
Lead sponsor
Richard Barry Moss
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Budesonide, budesonide/formoterol, Ipratropium/albuterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more
Conditions
Myopia
Interventions
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
Conditions
Mild Cognitive Impairment
Interventions
Donepezil, Atropine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Vitreous Floaters
Interventions
0.01% atropine ophthalmic drop
Drug
Lead sponsor
Jeanette Du
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reston, Virginia
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio